FDA grants accelerated approval to INOVIO's VOCERYQ for rare respiratory papillomatosis

what happened

INOVIO said the US Food and Drug Administration (FDA) has granted accelerated approval to VOCERYQ, a treatment meant to reduce how often adults with recurrent respiratory papillomatosis (RRP) need surgery. RRP is a rare disease in which papillomas often grow back after removal surgery.

In the RRP-001 study of 32 patients, 26 were included in the efficacy analysis. Seven of them (27%) needed no papilloma excision over 12 months of follow-up. INOVIO expects to take orders and ship the product in about 60 days, with full commercial launch planned for the first quarter of 2027. A confirmatory study is still required to verify clinical benefit.

why it matters

This is the first FDA-approved DNA medicine and a key milestone for INOVIO's platform, so it matters to investors in the company. It opens a path to revenue, but sales have not started, and the timing of the confirmatory study and the size of the market remain open questions. INOVIO estimates at least 25,000 RRP patients in the US.

market impact

INOVIO (INO): the approval removes a major regulatory uncertainty for its lead product, supporting the stock.

• ▲INOVIO (INO) pressure up — FDA approval removes a key regulatory risk for the company's first product

tags

instruments